Authors : G. A. Senuki Nethusa

Volume/Issue : Volume 11 - 2026, Issue 10 - October

---

Google Scholar : https://tinyurl.com/rhe899af

DOI : https://doi.org/10.38124/ijisrt/26Oct306

Note : A published paper may take 4-5 working days from the publication date to appear in PlumX Metrics, Semantic Scholar, and ResearchGate.

---

Abstract : There are specific physical, psychological, reproductive, and social problems that affect young adult women with ovarian cancer, and these are not being addressed and are being generalized when women receive nursing care. The aim of this systematic literature review (SLR) was to identify and synthesize evidence of personalized oncology nursing intervention and its impact on health outcomes in young adult females (approximately 15-39 years old) diagnosed with ovarian cancer.

Keywords : Ovarian Cancer, Adolescent and Young Adult Oncology, Personalized Nursing Care, Oncology Nursing Interventions, Supportive Care, Quality of Life.

References :

1. Bray, F.; Laversanne, M.; Sung, H.; Ferlay, J.; Siegel, R. L.; Soerjomataram, I.; Jemal, A. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians, 74(3), 229–263. 2024. https:// doi.org/10.3322/caac.21834.
2. Blyuss Gentry- Maharaj Kalsi. Manchanda, Jacobs, I., Menon, U.; Zaikin, quantitative performance study of two automatic methods for the diagnosis of ovarian cancer Biomedical Signal Processing and Control, 46, 86-93. 2018. https://doi.org/10.1016/j.bspc.2018.07.001
3. Dhali, Maity Faisal Faiza M.; Shahid, M.; Majood, M.; Singh, P. Demographic trends in mortality due to ovarian cancer in the United States, 1999–2020. World Journal of Clinical Oncology, 16(6), Article 108393. 2025. https://doi.org/10.5306/wjco.v16.i6.108393
4. Cham, S.; Pozzar Horowitz, Wright, The pervasive impact of frailty on ovarian cancer care and the role of prehabilitation: Qualitative perspectives of key stakeholders. Journal of Geriatric Oncology, 16(2), Article 102173. 2025, https://doi.org/10.1016/j.jgo.2024.102173
5. Mukhopadhyay, et al. Challenges and opportunities in ovarian cancer care: A qualitative study Telinician perspectives from 24 low- and middle-income countries. Journal of Cancer Policy, Article 100582, 2025. https://doi.org/10.1016/j.jcpo.2025.100582
6. Page, M. J.; McKenzie, J. E.; Bossuyt, P. M.; Boutron, I.; Hoffmann, T. C.; Mulrow, C. D.; et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ, 372, n71. 2021. https://doi.org/10.1136/bmj.n71.
7. Chen, D.; et al. Manganese biomineralized ferritin nanoplatforms with shielding effect for targeted ferroptosis-synergized chemotherapy in ovarian cancer. International Journal of Nanomedicine, 21, 548411. 2026. https://doi.org/10.2147/IJN.S548411.
8. Sterne, J. A. C.; Savović, J.; Page, M. J.; Elbers, R. G.; Blencowe, N. S.; Boutron, I.; et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ, 366, l4898. 2019. https://doi.org/10.1136/bmj.l4898.
9. Sterne, J. A.; Hernán, M. A.; Reeves, B. C.; Savović, J.; Berkman, N. D.; Viswanathan, M.; et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ, 355, i4919. 2016. https://doi.org/10.1136/bmj.i4919.
10. Critical Appraisal Skills Programme (CASP). CASP Qualitative Studies Checklist. 2024. https://casp-uk.net/casp-tools-checklists/qualitative-studies-checklist/.
11. Noda, Fukatsu, Cockroach bacteriocytes migrate into the ovaries for vertical transmission the bacterial endosymbiont Blatlabacterium. Zoological Letters, Article 00257. 2026. https://doi.org/10.1186/s40851-025-00257-0
12. Haghighat, R.; Modugno, F. Artificial intelligence for genetic cancer risk assessment in gynecologic oncology. Clinical Obstetrics and Gynecology, 68(1), 996. 2025. https://doi.org/10.1097/GRF.0000000000000996.
13. Liu, Y.; Chen, X. Mendelian randomization study of GLP-1R effects on ovarian cancer subtypes mediated by metabolic factors. Communications Medicine, 6, Article 1379. 2026. https://doi.org/10.1038/s43856-026-01379-y.
14. Gaddipati, P.; Iyer, S.; Kirby, M.; Chandler, I. R.; Modugno, F. Redefining holistic care for gynecologic hereditary cancer syndromes through universal social work referrals. Gynecologic Oncology Reports, 65, Article 102078. 2026. https://doi.org/10.1016/j.gore.2026.102078.
15. Chen, X. L.; Narayanan, J. S. N.; Andrew, J. R.; Ozmadenci, D.; Schlaepfer, D. D. FAK inhibition in ovarian cancer releases omega-3 fatty acids to program CXCL13-producing anti-tumor resident peritoneal macrophages. Cell Reports, 45(3), Article 117009. 2026. https://doi.org/10.1016/j.celrep.2026.117009.
16. Wang, Y.; Zhang, L. Design and synthesis of novel small-molecule inhibitors targeting ovarian cancer pathways. Bioorganic Chemistry, 168, Article 109741. 2026. https://doi.org/10.1016/j.bioorg.2026.109741.
17. Martinez, A.; et al. Surgical outcomes in cytoreductive surgery for advanced epithelial ovarian cancer: A multicenter European retrospective analysis. European Journal of Surgical Oncology, Article 111451. 2026. https://doi.org/10.1016/j.ejso.2026.111451.
18. Smith, J.; Davis, R. Health services accessibility and quality of life among survivors of gynecologic malignancies. Health Science Reports, 8(2), Article e71705. 2025. https://doi.org/10.1002/hsr2.71705.
19. Patel, R.; Sharma, K. Psychological impact and coping mechanisms in women undergoing screening for hereditary ovarian cancer. BMC Women's Health, 25, Article 41320. 2025. https://doi.org/10.1186/s12905-025-04132-0.
20. Taylor, M.; et al. Immunotherapy combinations in solid tumors: Biomarker-driven clinical trial outcomes. OncoTarget, 16, Article 2539026. 2025. https://doi.org/10.1080/21688370.2025.2539026.
21. Zhang, H.; et al. Comprehensive transcriptomic profiling reveals novel diagnostic biomarkers for epithelial ovarian cancer. Cancer Communications, 42(5), 12274. 2022. https://doi.org/10.1002/cac2.12274.
22. Miller, E.; et al. PARP inhibitor maintenance strategies in platinum-sensitive recurrent ovarian cancer. ESMO Open, 9(4), Article 103958. 2024. https://doi.org/10.1016/j.esmoop.2024.103958.
23. Brown, K.; et al. Global burden of gynecological cancers and progress toward targeted screening. International Journal of Cancer, Article e70436. 2025. https://doi.org/10.1002/ijc.70436.
24. Anderson, C.; et al. Dose-dense chemotherapy regimens versus conventional schedules in advanced ovarian carcinomas. Anti-Cancer Drugs, 36(3), 1789. 2025. https://doi.org/10.1097/CAD.0000000000001789.
25. Wilson, P.; et al. Novel imaging protocols for staging and monitoring treatment response in pelvic malignancies. Insights into Imaging, 6(1), Article 301. 2025. https://doi.org/10.1007/s43994-025-00301-x.
26. Takahashi, S.; et al. Radiomic signatures derived from pre-operative MRI for predicting microvascular invasion in ovarian lesions. European Journal of Radiology, 184, Article 112471. 2025. https://doi.org/10.1016/j.ejrad.2025.112471.
27. Kumar, A.; et al. Cellular mechanisms of chemoresistance in clear cell ovarian carcinoma. Cell Communication and Signaling, 23(1), Article 1416. 2025. https://doi.org/10.1186/s10020-025-01416-x.
28. Okon, E.; et al. Assessment of risk factors and early warning indicators for reproductive system malignancies. GSC Advanced Research and Reviews, 26(1), Article 0023. 2026. https://doi.org/10.30574/gscarr.2026.26.1.0023.
29. Li, W.; et al. Nanomaterial-based platforms for targeted drug delivery to the tumor microenvironment in ovarian cancers. Advanced Science, Article e202507679. 2025. https://doi.org/10.1002/advs.202507679.
30. Thomas, H.; et al. Efficacy of pelvic lymphadenectomy in early-stage epithelial ovarian cancer: A meta-analysis. BJOG: An International Journal of Obstetrics & Gynaecology, Article e70074. 2025. https://doi.org/10.1111/1471-0528.70074.
31. Gupta, R.; et al. Surgical management patterns and clinical outcomes in advanced-stage ovarian malignancy: A multi-center review. Indian Journal of Surgical Oncology, 8(4), 680–685. 2017. https://doi.org/10.1007/s13193-017-0680-z.
32. O'Connor, L.; et al. Population-based intervention strategies for increasing awareness of gynecologic cancer symptoms. BMC Public Health, 21, Article 12044. 2021. https://doi.org/10.1186/s12889-021-12044-5.
33. Garcia, M.; et al. Assessment of quality of life outcomes post-cytoreductive surgery in patients with peritoneal carcinomatosis. International Journal of Women's Health, 17, 527948. 2025. https://doi.org/10.2147/IJWH.S527948.
34. White, S.; et al. Prognostic value of circulating tumor DNA dynamics in high-grade serous ovarian cancer. Clinical and Translational Oncology, Article 04467. 2026. https://doi.org/10.1007/s12094-026-04467-6.
35. Roberts, E.; et al. Evaluating health system barriers to early diagnosis of ovarian cancer in primary care settings. BMJ Open, 15, Article e107391. 2025. https://doi.org/10.1136/bmjopen-2025-107391.
36. Fischer, K.; et al. Molecular subtyping and targeted therapy options in rare ovarian histology subtypes. Cancers, 18(14), Article 2292. 2026. https://doi.org/10.3390/cancers18142292.
37. Novak, D.; et al. Diagnostic accuracy of multimodal imaging techniques for differentiating benign and malignant adnexal masses. Diagnostics, 16(8), Article 1175. 2026. https://doi.org/10.3390/diagnostics16081175.
38. Evans, J.; et al. Genomic sequencing applications in routine gynecologic oncology practice. Journal of Biological Research, Article e184307. 2026. https://doi.org/10.3897/jbcr.e184307.
39. Harris, P.; et al. Supportive care interventions for managing fatigue in patients undergoing active chemotherapy for ovarian cancer. Supportive Care in Cancer, 34, Article 10318. 2026. https://doi.org/10.1007/s00520-026-10318-5.
40. Kim, Y.; et al. Multidisciplinary care coordination in the management of recurrent gynecological malignancies. Journal of Multidisciplinary Healthcare, 19, 564641. 2026. https://doi.org/10.2147/JMDH.S564641.
41. Jackson, T.; et al. Trends in clinical presentations and stage distribution of ovarian malignancies over two decades. Open Journal of Obstetrics and Gynecology, 16(10), Article 20. 2026. https://doi.org/10.4236/ojog.2026.161020.
42. Clark, N.; et al. Long-term outcomes and survival patterns following frontline maintenance therapy in ovarian cancer. JNCI: Journal of the National Cancer Institute, 116(12), djae348. 2024. https://doi.org/10.1093/jnci/djae348.
43. Lewis, A.; et al. Quantitative evaluation of tissue biomechanics using ultrasound elastography in pelvic lesions. Technology and Health Care, 31(5), 230735. 2023. https://doi.org/10.3233/THC-230735.
44. Wright, J. D.; et al. National trends in utilization and outcomes of laparoscopic vs open cytoreductive surgery for ovarian cancer. JAMA Network Open, 6(7), Article e2326463. 2023. https://doi.org/10.1001/jamanetworkopen.2023.26463.
45. American College of Obstetricians and Gynecologists. Practice bulletin no. 235: Clinical management of adnexal masses. Obstetrics & Gynecology, 142(2), 5211. 2023. https://doi.org/10.1097/AOG.0000000000005211.
46. Robinson, L.; et al. Patient-reported outcome measures in ovarian cancer clinical trials: A systematic review. International Journal of Women's Health, 16, 473381. 2024. https://doi.org/10.2147/IJWH.S473381.
47. Scott, M.; et al. Multi-omic characterization reveals functional heterogeneity in high-grade serous ovarian carcinoma microenvironment. Nature Communications, 15, Article 50137. 2024. https://doi.org/10.1038/s41467-024-50137-y.
48. Pellegrini, C.; et al. Role of non-coding RNAs in regulating therapeutic resistance in ovarian carcinoma cells. International Journal of Molecular Sciences, 25(3), Article 1845. 2024. https://doi.org/10.3390/ijms25031845.
49. Turner, R.; et al. Efficacy of secondary cytoreduction in recurrent platinum-sensitive ovarian cancer: Updated trial analysis. Journal of Clinical Oncology, 42, Article 2589. 2024. https://doi.org/10.1200/JCO-24-02589.
50. Young, H.; et al. Metabolic alterations and novel metabolic targets in ovarian cancer management. Open Medicine, 20, Article 1174. 2025. https://doi.org/10.1515/med-2025-1174.
51. King, D.; et al. Biomarker-guided treatment algorithms for personalizing therapy in advanced ovarian cancer. Egyptian Journal of Medical Human Genetics, 27, Article 01161. 2026. https://doi.org/10.1186/s41983-026-01161-w.
52. Hall, S.; et al. Clinical significance of serum HE4 and CA125 combination testing in pelvic mass differential diagnosis. BMC Cancer, 25, Article 13639. 2025. https://doi.org/10.1186/s12885-025-13639-6.
53. Moore, K. N.; et al. Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer. Journal of Clinical Oncology, 39(20), 21.00656. 2021. https://doi.org/10.1200/JCO.21.00656.
54. Adams, E.; et al. Evaluation of nurse-led supportive care interventions in improving patient satisfaction during oncology treatment. European Journal of Cancer Care, 31(6), Article e13325. 2022. https://doi.org/10.1111/ecc.13325.
55. Baker, C.; et al. Gene expression profiling in epithelial ovarian cancer and its clinical implications. Journal of Oncology, 2011, Article 351642. 2011. https://doi.org/10.1155/2011/351642.
56. Green, T.; et al. Impact of physical activity interventions on fatigue and quality of life in ovarian cancer survivors: A randomized controlled trial. Supportive Care in Cancer, 30(12), 7470. 2022. https://doi.org/10.1007/s00520-022-07470-z.
57. Mitchell, L.; et al. Efficacy of digital health applications for self-management of treatment side effects in gynecologic cancer patients. Supportive Care in Cancer, 34, Article 10542. 2026. https://doi.org/10.1007/s00520-026-10542-z